Olmesartán Normon (Olmesartan Medoxomil)

Olmesartan medoxyl selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to relaxed blood vessels, reduced peripheral resistance, and lower blood pressure, helping to protect the cardiovascular system.

The dose of Olmesartán Normon is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. The prescriber determines the appropriate strength and titration schedule.

Olmesartan medoxyl is contraindicated in the second and third trimesters of pregnancy because it can cause fetal toxicity. Limited data are available for breastfeeding; therefore, use is generally discouraged unless the benefit outweighs potential risk.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Olmesartan belongs to the ARB class, offering blood‑pressure control similar to other ARBs like losartan or valsartan but with a longer half‑life that may allow once‑daily dosing. Unlike ACE inhibitors, it is less likely to cause a dry cough.

Store Olmesartán Normon at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Do not expose the tablets to excessive heat or humidity.

Olmesartán Normon is taken orally, usually once daily, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether to take the medication at the same time each day.

Serious adverse events include angio‑edema, severe hypotension, hyper‑kalemia, and acute kidney injury. Patients should seek immediate medical attention if they experience swelling of the face, lips or throat, sudden dizziness, or a rapid decline in kidney function.

Olmesartan is contraindicated in patients with known hypersensitivity to olmesartan or any tablet excipients, and it should be avoided in pregnant women during the second and third trimesters. Caution is advised for individuals with severe renal impairment or those taking potassium‑raising agents.